| First Author | Masone A | Year | 2023 |
| Journal | iScience | Volume | 26 |
| Issue | 9 | Pages | 107480 |
| PubMed ID | 37636075 | Mgi Jnum | J:339648 |
| Mgi Id | MGI:7523704 | Doi | 10.1016/j.isci.2023.107480 |
| Citation | Masone A, et al. (2023) A tetracationic porphyrin with dual anti-prion activity. iScience 26(9):107480 |
| abstractText | Prions are deadly infectious agents made of PrP(Sc), a misfolded variant of the cellular prion protein (PrP(C)) which self-propagates by inducing misfolding of native PrP(C). PrP(Sc) can adopt different pathogenic conformations (prion strains), which can be resistant to potential drugs, or acquire drug resistance, hampering the development of effective therapies. We identified Zn(II)-BnPyP, a tetracationic porphyrin that binds to distinct domains of native PrP(C), eliciting a dual anti-prion effect. Zn(II)-BnPyP binding to a C-terminal pocket destabilizes the native PrP(C) fold, hindering conversion to PrP(Sc); Zn(II)-BnPyP binding to the flexible N-terminal tail disrupts N- to C-terminal interactions, triggering PrP(C) endocytosis and lysosomal degradation, thus reducing the substrate for PrP(Sc) generation. Zn(II)-BnPyP inhibits propagation of different prion strains in vitro, in neuronal cells and organotypic brain cultures. These results identify a PrP(C)-targeting compound with an unprecedented dual mechanism of action which might be exploited to achieve anti-prion effects without engendering drug resistance. |
